Pricing Log in Create free account
Saturday 17 October 2026 Export OMCL’s income statement to Excel — free account

Omnicell, Inc.

OMCL Healthcare Health Information Services

Omnicell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 6.53% from fiscal 2024. In the quarter to June 2026, revenue grew 7.45%, EPS grew 341.7%, free cash flow grew 107.9% and total debt fell 50.8%, each against the same quarter a year earlier.

35.39 0.56 −1.56%
Market cap
$1.6B
P/E
41.6×
Fwd P/E
55.1×
Dividend yield
—
F-score
7/9
Altman Z
2.69
Beneish M
−2.85
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.04
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 3 1 1 1 — 2 — 1 1 — —
Insider Ownership 3.40%

Capital & Financial Ratios $m

Market Cap 1,640.00
Revenue 1,246.70
Net Income 39.08
Free Cash Flow 126.77
Net Debt (123.96)
Current Ratio 1.64 (at or above 1.5: strong)
Debt/Equity 0.13 (at or below 0.5: strong)
P/E ratio 41.64 (above 35: high)
Fwd P/E 55.10 (above 35: high)
P/S ratio 1.29
P/B ratio 1.25
Past 5Y EPS Growth (44.21%) (below 0%: weak)
This Y EPS Growth 40.05% (at or above 15%: strong)
Next Y EPS Growth (9.42%) (below 0%: weak)
Next Y revenue growth 4.40%
Next 5Y EPS Growth 13.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.3×, against a ten-year median of 2.6×; over the ten years it ranged from 1.1× in 2024 to 7.3× in 2021.
P/E against its own 10 years 6.70%
10-year low 10-year high
P/S against its own 10 years 11.24%
10-year low 10-year high
P/B against its own 10 years 12.20%
10-year low 10-year high
EV/Sales against its own 10 years 10.87%
10-year low 10-year high
EV/FCF against its own 10 years 12.92%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 468 369 197 292
Receivables 252 256 217 227
Inventory 110 89 101 97
Other 72 75 132 84
928 815 680 735
2023 2024 2025 Q'26
Payables 45 52 44 50
ST’ Debt — 174 — —
Other — — — —
368 596 477 447

Compound Annual Growth %

10y 5y 3y
Sales 9.35% 5.84% (2.94%)
Cash Flow 12.71% (7.29%) 17.85%
Earnings (23.72%) (42.34%) (28.64%)
Book Value 11.84% 4.95% 2.91%

Revenue $m

Mar Jun Sep Dec Year
’26 310 312 — — —
’25 270 291 311 314 1,185
’24 246 277 282 307 1,112
’23 291 299 299 259 1,147
’22 319 331 348 298 1,296
’21 252 273 296 311 1,132
’20 230 200 214 249 892
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 55 68 — — —
’25 26 43 28 30 127
’24 50 59 23 56 188
’23 13 73 57 38 181
’22 (16) (10) 21 82 78
’21 57 72 43 60 232
’20 25 48 37 76 186
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 39 56 — — —
’25 10 27 14 18 69
’24 38 45 9 43 135
’23 (1) 58 43 26 126
’22 (31) (22) 5 65 17
’21 44 58 27 43 173
’20 11 28 27 65 131
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.25 0.52 — — —
’25 (0.15) 0.12 0.12 (0.05) 0.04
’24 (0.34) 0.08 0.19 0.34 0.27
’23 (0.33) 0.08 0.12 (0.32) (0.45)
’22 0.17 0.20 0.37 (0.64) 0.12
’21 0.30 0.43 0.61 0.28 1.62
’20 0.26 (0.10) 0.20 0.37 0.74
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 25.06 31.85 39.75 57.81 54.24 115.78 46.11 28.72 25.12 22.66

Analyst estimates 2026–2028

Powerpack
High 40.50 55.40 79.48 92.59 125.00 187.29 182.77 77.14 55.75 47.69
People
People Employees 2,444 2,350 2,480 2,700 2,860 3,800 4,230 3,650 3,670 3,580
Revenue/emp, $m 0.28 0.30 0.32 0.33 0.31 0.30 0.31 0.31 0.30 0.33
Income, $m
Income, $m Revenue 696 713 787 897 892 1,132 1,296 1,147 1,112 1,185
Gross margin, % 45.56 44.71 47.29 48.71 46.32 49.00 45.45 43.31 42.35 42.49
EBT 13 5 36 74 29 66 (2) (20) 26 11
EBT margin, % 1.86 0.63 4.52 8.24 3.29 5.83 (0.19) (1.75) 2.30 0.96
Net income 10 31 38 61 32 78 6 (20) 13 2
Depreciation 60 53 54 66 78 107 103 100 94 89
Per share, $
Per share, $ Revenue 19.25 19.01 20.06 21.63 20.95 26.04 29.19 25.37 24.15 25.78
Earnings 0.27 0.81 0.96 1.48 0.76 1.79 0.13 (0.45) 0.27 0.04
Cash flow 1.38 0.66 2.65 3.50 4.36 5.33 1.75 4.01 4.08 2.77
Capex (0.81) (0.81) (1.39) (1.49) (1.29) (1.34) (1.37) (1.22) (1.15) (1.26)
Free cash flow 0.57 (0.15) 1.26 2.01 3.08 3.99 0.38 2.79 2.93 1.51
Book value 11.94 14.79 17.32 20.39 22.72 26.38 25.45 26.30 27.00 26.80
Shares, m 36 37 39 41 43 43 44 45 46 46
Valuation, ×
Valuation, × P/E 128.36 86.77 63.79 55.22 155.87 100.80 368.14 0.00 164.89 1,132.50
P/S 1.79 2.60 3.05 3.78 5.73 6.93 1.77 1.47 1.84 1.76
P/B 2.88 3.35 3.54 4.01 5.28 6.84 2.02 1.42 1.65 1.69
EV/Sales 2.07 2.85 3.16 3.70 5.72 7.09 1.96 1.57 1.82 1.88
EV/FCF 69.61 (356.25) 50.19 39.85 38.96 46.25 148.79 14.28 14.98 32.12
Cash, $m
Cash, $m Operating cash flow 50 25 104 145 186 232 78 181 188 127
Capex (29) (31) (54) (62) (55) (58) (61) (55) (53) (58)
Free cash flow 21 (6) 50 83 131 173 17 126 135 69
Balance, $m
Balance, $m Working capital 134 147 193 246 553 (95) 453 560 220 203
Total debt 254 210 135 60 479 528 578 570 341 168
Net debt 200 178 68 (67) (7) 179 247 102 (28) (29)
Shareholders’ equity 432 554 680 845 968 1,147 1,130 1,189 1,243 1,232
Returns, %
Returns, % ROA 1.29 3.13 3.60 5.28 2.10 3.92 0.26 (0.92) 0.58 0.10
ROIC 2.12 0.95 3.71 6.29 2.31 4.22 (0.11) (1.69) 0.02 0.27
ROE 2.34 6.19 6.12 8.05 3.55 7.36 0.50 (1.76) 1.03 0.17
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Omnicell, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PRVA Privia Health Group, Inc. $2.9B 102× 87.8× +21.39% (above 0%: growing) +250.00% (above 0%: growing) −86.20% (below 0%: shrinking) 9.93% 1.86% Compare
SDGR Schrodinger, Inc. $1.9B — (loss-making) — (loss-making) +7.54% (above 0%: growing) n/m +34.43% (above 0%: growing) 55.07% (70.55%) Compare
OMCL Omnicell, Inc. $1.6B 41.6× 55.1× +7.45% (above 0%: growing) +341.67% (above 0%: growing) +107.90% (above 0%: growing) 48.98% 10.39%
CERT Certara, Inc. $1.5B — (loss-making) — (loss-making) +0.99% (above 0%: growing) n/m −78.46% (below 0%: shrinking) 62.34% (0.21%) Compare
GDRX GoodRx Holdings, Inc. $1.2B 62.7× 30.9× −1.31% (below 0%: shrinking) −25.00% (below 0%: shrinking) +112.45% (above 0%: growing) 89.52% 11.79% Compare
OMDA Omada Health, Inc. $1.1B 252× 143× +43.12% (above 0%: growing) n/m +45.71% (above 0%: growing) 72.62% 4.04% Compare
TDOC Teladoc Health, Inc. $1.1B — (loss-making) — (loss-making) −3.95% (below 0%: shrinking) n/m −27.07% (below 0%: shrinking) 68.56% (6.11%) Compare
HSTM HealthStream, Inc. $1.0B 46.0× 34.4× +12.55% (above 0%: growing) +27.78% (above 0%: growing) +362.71% (above 0%: growing) 65.35% 9.94% Compare
PHR Phreesia, Inc. $685.3M 64.4× 23.5× +10.41% (above 0%: growing) +200.00% (above 0%: growing) +43.51% (above 0%: growing) 66.64% 5.88% Compare
Median of peers $1.2B 64.4× 34.4× +8.98% +113.89% +38.97% 66.00% 2.95%

All 51 Health Information Services stocks →

Omnicell, Inc. (OMCL) key facts

  • Strength: Omnicell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 6.53% from fiscal 2024.
  • Omnicell, Inc. (OMCL) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, OMCL traded at $35.39, a market capitalization of $1.6 billion.
  • Return on equity was 0.17% and debt-to-equity 0.13.
  • Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 2.69 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Omnicell, Inc. (OMCL) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/OMCL · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com